Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 18/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 17/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 12/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825037 | 0.93 | AKR1B10 (0.86) | AKR1B1AKR1B10AKR1A1PLA2G1BPLA2G2A | |
| SCHEMBL2820642 | 0.90 | AKR1B1 (0.81) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL2824165 | 0.89 | AKR1B10 (0.80) | AKR1B1AKR1B10AKR1A1PLA2G1BPLA2G2A | |
| SCHEMBL13857709 | 0.88 | AKR1B10 (0.79) | AKR1B1AKR1B10AKR1A1PLA2G1BPLA2G2A | |
| SCHEMBL2824962 | 0.87 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL2845416 | 0.87 | AKR1B1 (0.81) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL2820228 | 0.86 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9914991 | 0.85 | AKR1B1 (0.81) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9913674 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL2846607 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198447-B2 | Fused tricyclic compound having aldose reductase inhibitory activity | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8198447-B2 | Fused tricyclic compound having aldose reductase inhibitory activity | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145052-A1 | FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY | AKR1C4, AKR1C2, AKR1C3 | AKR1B1 4/4885AKR1B10 10/4885AKR1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.